MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

A

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Search

Onconova Therapeutics Inc

Geschlossen

0

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+277.91% upside

Onconova Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Apr. 2026, 23:17 UTC

Ergebnisse

Samsung Forecasts Record First-Quarter Operating Profit

6. Apr. 2026, 23:00 UTC

Heiße Aktien

Stocks to Watch: Health Insurers, Mawson, Owlet

6. Apr. 2026, 22:13 UTC

Wichtige Markttreiber

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6. Apr. 2026, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6. Apr. 2026, 17:09 UTC

Wichtige Markttreiber

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6. Apr. 2026, 16:56 UTC

Wichtige Nachrichtenereignisse

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6. Apr. 2026, 14:47 UTC

Wichtige Markttreiber

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6. Apr. 2026, 23:58 UTC

Market Talk
Wichtige Nachrichtenereignisse

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6. Apr. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6. Apr. 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6. Apr. 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6. Apr. 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6. Apr. 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6. Apr. 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6. Apr. 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6. Apr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6. Apr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Apr. 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. Apr. 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6. Apr. 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6. Apr. 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6. Apr. 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6. Apr. 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6. Apr. 2026, 18:36 UTC

Akquisitionen, Fusionen, Übernahmen

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. Apr. 2026, 17:59 UTC

Market Talk
Wichtige Nachrichtenereignisse

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6. Apr. 2026, 17:13 UTC

Akquisitionen, Fusionen, Übernahmen

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. Apr. 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6. Apr. 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Apr. 2026, 14:59 UTC

Ergebnisse

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer-Vergleich

Kursveränderung

Onconova Therapeutics Inc Prognose

Kursziel

By TipRanks

277.91% Vorteil

12-Monats-Prognose

Durchschnitt 6.5 USD  277.91%

Hoch 6.5 USD

Tief 6.5 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Onconova Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Finanzen

$

help-icon Live chat